Table 3.

Graphene oxide (GO)– hyaluronic acid (HA) composites, their size, the drug used, type of cancer cell treated, drug loading, and release efficiency.

GO–HA Nanocomposites	Size	Drug Used	Cancer Cell Line	Drug Loading Efficiency	Drug Release Efficiency	Reference
GO–HA	40–350 nm	DOX	HeLa human cervical cancer cells (L-929)	81.5%	6.8% for pH 7.4, 10.9% for pH 6.3, 26% at pH 5.2	[154]
GO–HA	78.1 nm	Photosensitizer Ce6	Human cervical cancer cells (HeLa) cells and mouse embryonic fibroblast cells (NIH3T3)	115%	7% at pH 5, 22% at pH 7, and 30% at pH 9	[155]
GO–HA–RGD peptide	70–490 nm	DOX	Human ovarian cancer cells (SKOV-3)	72.9%	30.2% at pH 5.5, 7.6% at pH 7.4	[156]
NGO–SS–HA	125 nm	Gef	Adenocarcinomic human alveolar basal epithelial cells (A549)	13.8%	30.8% in absence of GSH, 60.1% in presence of GSH	[153]
NGO–HA	250 nm	Epirubicin	Murine melanoma cells (B16F1)	2% at pH 4, 9% at pH 7, 25% at pH 9	70% at pH 5, 18% at pH 7	[152]
GO–HA, later combined with iron oxide NPs for magnetic field-enabled chemotherapy for better cancer cell inhibition	166.8 ± 16.2 nm	DOX, PTX	Human breast cancer cells (MDA-MB-231)	33.5 ± 1.4%	53% at pH 7.4, 61% at pH 5.5	[158]
GO–HA	10−200 nm	DOX	Human liver cancer cells (HepG2)	42.9%	20% at pH 7.4, 40% at pH 5.3	[151]
rGO–HA-g-PMAO	108 nm	Used for PTT	MCF-7 human breast cancer cells	-	-	[157]